VistaGen Therapeutics (VTGN) Misses Q2 EPS by 1c

VistaGen Therapeutics (NASDAQ: VTGN) reported Q2 EPS of ($0.08), $0.01 worse than the analyst estimate of ($0.07).

For earnings history and earnings-related data on VistaGen Therapeutics (VTGN) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Alphabet slides over 6% as AI brain drain and SpaceX slump converge
• C.H. Robinson acquires DeSpir Logistics for $75 million